SYNTHETIC DEMONSTRATION — no real student or patient. Not a medical device.

allergy-asthma

Biologic Medications for Severe Asthma: What to Know

Biologic medications are injected or infused treatments that target specific immune pathways driving severe asthma. Used when inhaled corticosteroids and standard controllers are insufficient, approved options include omalizumab (Xolair), dupilumab (Dupixent), mepolizumab (Nucala), and benralizumab (Fasenra). An allergist or pulmonologist prescribes and monitors them.

Talk to a clinician

Gale can match you with a licensed clinician for a visit.

Find care →

What makes asthma "severe" or "uncontrolled"?

Most people with asthma achieve good control with low-to-medium doses of inhaled corticosteroids, sometimes combined with a long-acting bronchodilator. Severe asthma is defined as asthma that remains uncontrolled despite high-dose inhaled therapy — with frequent exacerbations, oral steroid dependence, or significant limitation of daily activities despite adherence to treatment. 1

Before adding a biologic, clinicians confirm: - Correct inhaler technique - Adherence to the prescribed regimen - That alternative diagnoses (COPD, vocal cord dysfunction, cardiac causes) have been considered - That major triggers have been addressed

How do biologics for asthma work?

Biologic medicines are antibodies engineered to block a specific protein in the inflammatory cascade. Most approved asthma biologics target the "type 2" pathway — the branch of the immune response driven by eosinophils (a type of white blood cell) and IgE antibodies. 12

The main targets: - IgE — the antibody that triggers allergic reactions. Omalizumab (Xolair) binds free IgE, reducing the signal that causes airway inflammation in allergic asthma. - IL-5 and IL-5 receptor — a signaling protein that drives eosinophil production. Mepolizumab (Nucala) and reslizumab (Cinqair) block IL-5; benralizumab (Fasenra) blocks its receptor. - IL-4 and IL-13 receptors — cytokines central to type-2 inflammation. Dupilumab (Dupixent) blocks the shared receptor, reducing both eosinophil-driven and IgE-driven inflammation; it also treats eczema and nasal polyps through the same mechanism. - TSLP — an upstream alarm signal from airway cells. Tezepelumab (Tezspire) blocks TSLP and is notable for working even in patients without high eosinophil counts.

The 2020 NHLBI Focused Updates to the Asthma Management Guidelines addressed step-up therapy decision-making for patients with severe uncontrolled asthma, including when specialist referral for biologic evaluation is appropriate. 3

Who might qualify for a biologic?

Eligibility is based on documented severe uncontrolled asthma plus specific biomarker profiles 1:

  • Elevated blood eosinophils (measured by a simple blood count) — relevant to IL-5 and dupilumab therapies
  • Elevated total IgE and evidence of allergic sensitization — relevant to omalizumab (Xolair)
  • Fractional exhaled nitric oxide (FeNO) — a breath test that reflects type-2 airway inflammation; used alongside eosinophil counts

Tezepelumab has broader applicability because it works upstream of these markers, though it is used in the same severe-asthma population.

Biologics are generally not used for mild or moderate asthma that responds to standard inhalers. An allergist or pulmonologist interprets the biomarkers and matches the right biologic to each person's pattern.

Do these treatments actually work?

Clinical trials for approved asthma biologics consistently show reductions in the rate of severe exacerbations — significant flare-ups requiring systemic steroids or hospitalization — compared to placebo, in appropriately selected patients. 12 Many patients also experience reduced oral steroid dependence and improved quality of life.

Response is not uniform. Some people see dramatic improvement; others have more modest benefit. Trials typically run 6–12 months before a full assessment of response. If one biologic doesn't work well, switching to one with a different target is sometimes considered.

Biologics do not cure asthma. Most patients continue their inhaled controller therapy alongside the biologic.

How are they given and monitored?

Most asthma biologics are given by injection every 2–8 weeks, either self-injected at home with a pen or given in a clinician's office. Omalizumab (Xolair) and reslizumab are given by infusion or injection in a healthcare setting, with a 30-minute observation period for Xolair due to a small risk of delayed allergic reaction.

Monitoring typically includes: - Spirometry (breathing test) to assess lung function - Blood eosinophil counts - Symptom questionnaires to track control 2 - Review of exacerbation rate and any side effects

These medicines are expensive and require prior authorization from most insurance plans. An allergist's or pulmonologist's documentation of severity and biomarker eligibility is usually required.

Who manages biologic therapy for asthma?

Biologics for severe asthma are prescribed and managed by allergists or pulmonologists — specialists in lung disease and/or immune-mediated conditions. They conduct the pulmonary function testing, interpret biomarkers, obtain insurance authorization, and monitor for response and side effects.

A primary care or Gale clinician plays a supporting role: managing daily controller inhalers, recognizing when severity warrants specialist referral, and coordinating care between the specialist and any other providers. If you haven't been referred yet, a Gale clinician can assess your asthma control and help initiate that conversation.

Common questions

Can I stop my inhaler if I start a biologic?

Usually no, at least not right away. Biologics are add-on therapies for people who are already on high-dose inhaled corticosteroids. Some patients who respond well are eventually able to reduce their inhaled steroid dose under specialist guidance, but this happens gradually and is never a self-directed change.

Is Dupixent the same as the one used for eczema?

Yes. Dupilumab (Dupixent) is approved for both severe asthma (with eosinophilic or oral steroid-dependent disease) and moderate-to-severe atopic dermatitis (eczema), among other conditions. The underlying biology is related — both involve the IL-4/IL-13 signaling pathway. A single biologic can sometimes treat more than one condition if a person has both.

How long does it take for a biologic to work for asthma?

Some improvement in symptoms can appear within weeks, but the meaningful reduction in exacerbation rate is typically assessed over 6–12 months of treatment. Clinicians generally evaluate whether to continue the biologic at the 6-month mark based on symptom scores, lung function, and any flare-ups during treatment.

Are asthma biologics covered by insurance?

Most major insurance plans, including Medicare, cover approved asthma biologics for patients who meet specific clinical criteria. Prior authorization is nearly always required. Manufacturer patient assistance programs are available for those with coverage gaps. Your specialist's office typically handles this paperwork, but it can take several weeks.

Talk to a clinician

Gale can match you with a licensed clinician for a visit.

Find care →

Asthma warning signs that need immediate attention

  • —Rescue inhaler not helping and breathing worsens — call 911
  • —Blue or gray lips or fingertips — call 911
  • —Unable to speak in full sentences due to breathlessness — call 911
  • —Wheezing that stops suddenly in a severe attack (a sign of airways closing) — call 911
  • —Allergic reaction after a biologic injection: hives, throat tightening, severe dizziness — call 911

Call 911 for any severe breathing difficulty that does not quickly respond to a rescue inhaler.

This article is educational and does not substitute for individualized care by a specialist. Biologic therapy for severe asthma requires assessment, biomarker testing, and prescribing by an allergist or pulmonologist. Gale can help coordinate that referral.

References

  1. 1.Global Initiative for Asthma (GINA) Science Committee (2024). Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma. link ✓Biologic add-on therapy for severe uncontrolled asthma; criteria including eosinophil counts, IgE levels, and FeNO; treatment targets and monitoring
  2. 2.Venkatesan P (2023). 2023 GINA report for asthma. Lancet Respiratory Medicine. doi:10.1016/S2213-2600(23)00230-8 ✓Exacerbation reduction in appropriately selected patients receiving biologic therapy; monitoring with spirometry and symptom questionnaires
  3. 3.Cloutier MM, Baptist AP, Blake KV, et al. (Expert Panel Working Group, NAEPP) (2020). 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Journal of Allergy and Clinical Immunology. doi:10.1016/j.jaci.2020.10.003 ✓Add-on therapy recommendations for severe uncontrolled asthma not responding to high-dose inhaled corticosteroids

3 sources, numbered by first appearance. General health information, not medical advice — synthetic demonstration content.